Mayo, Baylor partner on precision medicine genome sequencing in biobank

- Print  | 

Rochester, Minn.-based Mayo Clinic and Houston-based Baylor College of Medicine are partnering to sequence DNA in Mayo's biobank to examine genomic markers to help identify possible drug reactions.

As part of the nationwide trend of precision medicine, Baylor's Human Genome Sequencing Center will assist in sequencing the DNA of 69 different genes that may influence how patients react to certain drugs. Such pharmacogenomic findings could then be placed in patients' medical records, providing early warnings to clinicians about which drugs may present problems for patients.

"This collaboration is a wonderful example of how a partnership between a genome center and a premier clinical group can speed the translation of valuable genomic tests into useful advances in patient care," said Richard Gibbs, PhD, director of the Human Genome Sequencing Center at Baylor.

More articles on genomics:

Geisinger opens Precision Health Center
What do genomics mean for the individual patient?
Rare Genomics Institute announces new director and CEO

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

To receive the latest hospital and health system business and legal news and analysis from Becker's Hospital Review, sign-up for the free Becker's Hospital Review E-weekly by clicking here.